Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops

Current Signal Transduction Therapy

Volumn 8, Issue 3, 2013, Pages 193-202

  Von Manstein, Viktoria ^a   Yang, Chul Min ^a   Richter, Diane ^a   Delis, Natalia ^a   Vafaizadeh, Vida ^a   Groner, Bernd ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Drug resistance; Signaling redundancy and compensation; Targeted tumor therapy

Indexed keywords

JANUS KINASE 2; PROTEIN KINASE P60; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84900549373     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574362409666140206221931     Document Type: Article

References (73)

1. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, et al. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012; 18: 127-39.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians 2012; 62: 10-29.
4. Gough NR. Focus issue: From genomic mutations to oncogenic pathways. Science signaling 2013; 6: eg3.
5. McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, et al. Advances in targeting signal transduction pathways. Oncotarget 2012; 3: 1505-21.
6. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature reviews Cancer 2012; 12: 237-51.
7. Gottesman MM. Mechanisms of cancer drug resistance. Annual review of medicine 2002; 53: 615-27.
8. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends in pharmacological sciences 2009; 30: 546-56.
9. Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem Pharmacol 2010; 80: 666-73.
10. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-37.
11. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nature reviews Cancer 2012; 12: 553-63.
12. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature reviews Drug discovery 2009; 8: 709-23.
13. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current opinion in genetics & development 2008; 18: 73-9.
14. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-smallcell lung cancer to gefitinib. The New England journal of medicine 2005; 352: 786-92.
15. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature reviews Cancer 2012; 12: 513-26.
16. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. The New England journal of medicine 2010; 363: 1734-9.
17. Sawyers CL. The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. Transactions of the American Clinical and Climatological Association 2012; 123: 114-23; discussion 23-5.
18. Workman P, Al-Lazikani B, Clarke PA. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current opinion in pharmacology 2013; 13: 486-96.
19. Groner B. Determinants of the extent and duration of STAT3 signaling. Jak-Stat 2012; 1: 211-5.
20. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in biochemical sciences 2011; 36: 320-8.
21. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes & development 2012; 26: 641-50.
22. Trusolino L, Bertotti A. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation. Cancer discovery 2012; 2: 876-80.
23. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science translational medicine 2011; 3: 75ra26.
24. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer cell 2010; 17: 77-88.
25. Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer discovery 2012; 2: 311-9.
26. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30: 2547-57.
27. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell 2011; 19: 58-71.
28. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer discovery 2011; 1: 248-59.
29. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer cell 2012; 22: 796-811.
30. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-90.
31. Groner B, Hennighausen L. The versatile regulation of cellular events by Jak-Stat signaling: from transcriptional control to microtubule dynamics and energy metabolism. Hormone Molecular Biology and Clinical Investigations 2012; 10: 193-200.
32. Groner B, Vafaizadeh V. Cytokine regulation of mammary gland development and epithelial cell functions through discrete activities of Stat proteins. Molecular and cellular endocrinology 2013.
33. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. The New England journal of medicine 2013; 368: 161-70.
34. Mertens C, Darnell JE, Jr. SnapShot: JAK-STAT signaling. Cell 2007; 131: 612.
35. Reich NC, Liu L. Tracking STAT nuclear traffic. Nature reviews Immunology 2006; 6: 602-12.
36. Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 7765-9.
37. Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, et al. Dynamics and non-canonical aspects of JAK/STAT signalling. European journal of cell biology 2012; 91: 524-32.
38. Priester M, Copanaki E, Vafaizadeh V, Hensel S, Bernreuther C, Glatzel M, et al. STAT3 silencing inhibits glioma single cell infiltration and tumor growth. Neuro-oncology 2013; 15: 840-52.
39. Fan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein & cell 2013; 4: 176-85.
40. Sellier H, Rebillard A, Guette C, Barre B, Coqueret O. How should we define STAT3 as an oncogene and as a potential target for therapy? Jak-Stat 2013; 2: e24716.
41. Bournazou E, Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. Jak-Stat 2013; 2: e23828.
42. Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K, et al. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem cells 2010; 28: 928-38.
43. Vafaizadeh V, Klemmt PA, Groner B. Stat5 assumes distinct functions in mammary gland development and mammary tumor formation. Frontiers in bioscience 2012; 17: 1232-50.
44. Fagard R, Metelev V, Souissi I, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? Jak- Stat 2013; 2: e22882.
45. Borghouts C, Delis N, Brill B, Weiss A, Mack L, Lucks P, et al. A membrane penetrating aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. Jak-Stat 2012; 1: 44-54.
46. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 9623-8.
47. Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, et al. Pharmacologic Inhibition of Jak2-Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2013; 19: 5658-74.
48. Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert opinion on pharmacotherapy 2012; 13: 2397-407.
49. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2010; 13: 67-78.
50. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13: 4233-44.
51. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2009; 15: 6852-61.
52. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janusactivated kinase-STAT3 binding. Cancer research 2009; 69: 1958- 65.
53. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer cell 2011; 19: 498-511.
54. Horwood NJ, Urbaniak AM, Danks L. Tec family kinases in inflammation and disease. International reviews of immunology 2012; 31: 87-103.
55. Jarboe JS, Dutta S, Velu SE, Willey CD. Mini-review: bmx kinase inhibitors for cancer therapy. Recent patents on anti-cancer drug discovery 2013; 8: 228-38.
56. Cohen I, Maoz M, Turm H, Grisaru-Granovsky S, Maly B, Uziely B, et al. Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance. PloS one 2010; 5: e11135.
57. Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, et al. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer research 2010; 70: 5587-96.
58. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature reviews Cancer 2009; 9: 798-809.
59. Couronne L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, et al. STAT3 mutations identified in human hematological neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013.
60. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. The Journal of experimental medicine 2011; 208: 1359-66.
61. Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nature reviews Drug discovery 2013; 12: 688-702.
62. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nature medicine 2010; 16: 1421-8.
63. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer cell 2009; 15: 283-93.
64. Heffernan-Stroud LA, Obeid LM. Sphingosine kinase 1 in cancer. Advances in cancer research 2013; 117: 201-35.
65. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer cell 2013; 23: 107-20.
66. Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, et al. Therapeutic potential of targeting SK1 in human cancers. Advances in cancer research 2013; 117: 143-200.
67. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis. Neoplasia 2013; 15: 848-62.
68. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem cells 2009; 27: 2393-404.
69. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer cell 2012; 21: 642-54.
70. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nature reviews Cancer 2012; 12: 494-501.
71. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. The lancet oncology 2013.
72. Groner B, Weber A, Mack L. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered 2012; 3: 320-5.
73. Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. Journal of medicinal chemistry 2012; 55: 1047-55.